Reporter brief
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)
What happened
Trial registry update: COMPLETED. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Observational design cannot establish causation and is susceptible to confounding by indication, unmeasured confounders, and selection bias
- Without reported effect sizes or sample characteristics, the clinical significance and applicability of any comparison cannot be assessed
- This abstract describes the study methodology and goals rather than results, so no clinical outcomes are established
Study design and sample
Observational; Human.
Not recorded.
- Design
- Observational
- Sample
- —
- Journal
- Brigham and Women's Hospital
- Published
- Sep 21, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the GLP-1 agonists timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.